The present study investigated the antitumor action of α1-adrenoceptor blockers on human bladder, prostate and renal cancer cells.
For bladder cancer cell lines used here such as 253J, 5637, KK-47, T24 and UM-UC-3 cells, prazosin, a selective α1-adrenoceptor blocker, reduced cell viability at concentrations more than 30 µmol/l. Likewise, naftopidil, a blocker of α1A- and α1D-adrenoceptors, reduced cell viability for all the bladder cancer cells used here in a concentration (10-100 µmol/l)-dependent manner, with a much greater advantage than prazosin. Naftopidil also reduced cell viability for human prostate cancer cell lines such as DU145, LNCap and PC-3 cells and ACHN human renal cancer cells, with a much higher potential than prazosin. Thus, the results of the present study suggest that naftopidil could be a beneficial antitumor drug for the treatment of urological cancers.
Written by:
Gotoh A, Nagaya H, Kanno T, Nishizaki T. Are you the author?
Laboratory of Cell and Gene Therapy, Institute for Advanced Medical Sciences, Hyogo College of Medicine, Nishinomiya, Japan.
Reference: Pharmacology. 2012;90(5-6):242-6.
doi: 10.1159/000342797
PubMed Abstract
PMID: 23007551
UroToday.com Investigative Urology Section
